These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24124705)

  • 41. SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS.
    Chinzon D; Domingues G; Tosetto N; Perrotti M
    Arq Gastroenterol; 2022; 59(2):219-225. PubMed ID: 35830032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxicity of long-term use of proton pump inhibitors in children.
    De Bruyne P; Ito S
    Arch Dis Child; 2018 Jan; 103(1):78-82. PubMed ID: 29237614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of proton pump-inhibiting drugs on mineral metabolism.
    Insogna KL
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S2-4. PubMed ID: 19262542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers.
    Laine L; Shah A; Bemanian S
    Gastroenterology; 2008 Jun; 134(7):1836-41. PubMed ID: 18423628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients.
    Reimer C; Bytzer P
    Aliment Pharmacol Ther; 2009 Oct; 30(7):725-32. PubMed ID: 19604180
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
    Juul-Hansen P; Rydning A
    Scand J Gastroenterol; 2011 Apr; 46(4):398-405. PubMed ID: 21142586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
    Aseeri M; Schroeder T; Kramer J; Zackula R
    Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton pump inhibitor side effects and drug interactions: much ado about nothing?
    Madanick RD
    Cleve Clin J Med; 2011 Jan; 78(1):39-49. PubMed ID: 21199906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of pharmacokinetic drug-drug-interactions. Critical considerations of the relevance of pharmacokinetic drug-drug interactions of proton pump inhibitors in self medication].
    Petersen KU
    Med Monatsschr Pharm; 2011 Aug; 34(8):270-8. PubMed ID: 21853881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin B12 levels during prolonged treatment with proton pump inhibitors.
    Howden CW
    J Clin Gastroenterol; 2000 Jan; 30(1):29-33. PubMed ID: 10636207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns.
    Hedberg J; Sundström J; Thuresson M; Aarskog P; Oldgren J; Bodegard J
    J Intern Med; 2013 Oct; 274(4):371-80. PubMed ID: 23800296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients.
    Niv Y
    Med Hypotheses; 2011 Sep; 77(3):451-2. PubMed ID: 21723045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmaceutical principles of acid inhibitors: unmet needs.
    Krznaric Z; Ljubas Kelecic D; Rustemovic N; Vranesic Bender D; Ostojic R; Markos P; Scarpignato C
    Dig Dis; 2011; 29(5):469-75. PubMed ID: 22095012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proton pump inhibitors: Risks of long-term use.
    Eusebi LH; Rabitti S; Artesiani ML; Gelli D; Montagnani M; Zagari RM; Bazzoli F
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1295-1302. PubMed ID: 28092694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential Cardiovascular Risks of Proton Pump Inhibitors in the General Population.
    Zhu W; Hong K
    Int Heart J; 2017 Apr; 58(2):163-166. PubMed ID: 28321021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton Pump Inhibitors: Review of Emerging Concerns.
    Nehra AK; Alexander JA; Loftus CG; Nehra V
    Mayo Clin Proc; 2018 Feb; 93(2):240-246. PubMed ID: 29406201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Consequences of Hypoacidity Induced by Proton Pump Inhibitors - a Practical Approach.
    Rychlíčková J
    Klin Onkol; 2018; 31(6):409-413. PubMed ID: 31035765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.